AXSM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXSM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Axsome Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $144.0 Mil. Axsome Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $545.7 Mil. Therefore, Axsome Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.26.
The historical rank and industry rank for Axsome Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 11 years, the highest Equity to Asset Ratio of Axsome Therapeutics was 0.95. The lowest was -1.15. And the median was 0.46.
The historical data trend for Axsome Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.81 | 0.61 | 0.18 | 0.33 | 0.33 |
Axsome Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.29 | 0.46 | 0.45 | 0.33 | 0.26 |
For the Biotechnology subindustry, Axsome Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Axsome Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 190.977 | / | 588.236 | |
= | 0.32 |
Axsome Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Equity to Asset (Q: Mar. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 144.036 | / | 545.728 | |
= | 0.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics (NAS:AXSM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Axsome Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Mark Coleman | director | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Hunter R. Murdock | officer: General Counsel | 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007 |
Roger Jeffs | director | |
Nick Pizzie | officer: Chief Financial Officer | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Mark E Saad | director | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Herriot Tabuteau | director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER | |
Mark L. Jacobson | officer: Chief Operating Officer | 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038 |
David C Marek | officer: Chief Commercial Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
John Golubieski | officer: Chief Financial Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
Myrtle S Potter | director | 10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
Randall Kaye | officer: Chief Medical Officer | 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
Ames Constance | officer: Vice President, Finance | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Antecip Capital Llc | 10 percent owner | 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111 |
From GuruFocus
By sperokesalga sperokesalga • 04-14-2023
By PRNewswire PRNewswire • 05-08-2023
By GlobeNewswire • 06-28-2023
By PRNewswire • 11-26-2023
By Business Wire • 09-29-2023
By Marketwired • 09-05-2023
By GuruFocus Research • 11-06-2023
By Marketwired • 09-07-2023
By sperokesalga sperokesalga • 05-30-2023
By PRNewswire PRNewswire • 02-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.